Skip to Main Content
Table 1—

Baseline characteristics of study patients

Baseline characteristicsPlaceboLosartanP
n 10 11 — 
Sex (M/F) 9/1 11/0 — 
Age (years) 63.1 (3.9) 60.5 (3.3) 0.62 
Duration of diabetes (years) 4.0 (1–10) 7.0 (1–38) 0.14 
BMI (kg/m228.1 (1.6) 29.9 (2.0) 0.50 
HbA1c (%) 7.4 (0.4) 7.8 (0.5) 0.48 
24-h urine sodium (mmol/day) 210 (26) 229 (33) 0.64 
Clinic MAP (mmHg) 110.6 (2.6) 114.5 (2.4) 0.29 
AER (μg/min) 32.6 [1.3] 21.3 [1.5] 0.36 
Plasma TGF-β (ng/ml) 2.3 [1.1] 2.0 [1.1] 0.31 
Urine TGF-β excretion (pg/min) 20.9 [1.1] 25.0 [1.2] 0.39 
Baseline characteristicsPlaceboLosartanP
n 10 11 — 
Sex (M/F) 9/1 11/0 — 
Age (years) 63.1 (3.9) 60.5 (3.3) 0.62 
Duration of diabetes (years) 4.0 (1–10) 7.0 (1–38) 0.14 
BMI (kg/m228.1 (1.6) 29.9 (2.0) 0.50 
HbA1c (%) 7.4 (0.4) 7.8 (0.5) 0.48 
24-h urine sodium (mmol/day) 210 (26) 229 (33) 0.64 
Clinic MAP (mmHg) 110.6 (2.6) 114.5 (2.4) 0.29 
AER (μg/min) 32.6 [1.3] 21.3 [1.5] 0.36 
Plasma TGF-β (ng/ml) 2.3 [1.1] 2.0 [1.1] 0.31 
Urine TGF-β excretion (pg/min) 20.9 [1.1] 25.0 [1.2] 0.39 

Data are expressed as means (SE); AER and plasma and urinary TGF-β as geometric mean [TF]; and diabetes duration as median (range).

Close Modal

or Create an Account

Close Modal
Close Modal